Drug intelligence / Profile preview

SIR-T BCMA

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T BCMA is an investigational cell therapy developed by Angeles Therapeutics, utilizing their proprietary Synthetic Immune Receptor (SIR-T) platform to target B-cell maturation antigen (BCMA). Unlike traditional CAR-T therapies, the SIR-T platform aims to provide more physiological T-cell signaling, potentially improving the persistence and efficacy of the engineered cells against BCMA-expressing malignancies such as multiple myeloma. The program is currently undergoing IND-enabling studies to support future clinical trials.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on SIR-T BCMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T BCMA.

Explore the full profile